×
IBio Long Term Debt 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
IBio long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
View More
IBio Long Term Debt 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
IBio long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$159.1B
Vertex Pharmaceuticals (VRTX)
$124.6B
Bristol Myers Squibb (BMY)
$118.6B
Gilead Sciences (GILD)
$114.8B
CSL (CSLLY)
$88.8B
Regeneron Pharmaceuticals (REGN)
$86B
GSK (GSK)
$71.3B
Argenex SE (ARGX)
$35.6B
Alnylam Pharmaceuticals (ALNY)
$33.3B
BioNTech SE (BNTX)
$24.8B
Biogen (BIIB)
$24B
Illumina (ILMN)
$22.6B
BeiGene (BGNE)
$18.8B
Moderna (MRNA)
$15.3B
Incyte (INCY)
$15B
Genmab (GMAB)
$14B
Insmed (INSM)
$12.7B
BioMarin Pharmaceutical (BMRN)
$12.5B
Vaxcyte (PCVX)
$11.6B
Bio-Techne Corp (TECH)
$11.5B
Sarepta Therapeutics (SRPT)
$10.4B
Exelixis (EXEL)
$10B
Revolution Medicines (RVMD)
$9.7B
QIAGEN (QGEN)
$9.6B
Exact Sciences (EXAS)
$9.4B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.5B